FiercePharma

RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 18, 2013) - GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has ...
FiercePharma

RELVAR™ ELLIPTA™ receives positive opinion from the CHMP in Europe for the treatment of asthma and COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a ...
Medscape

CHMP Backs Relvar Ellipta for Asthma, COPD

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for fluticasone furoate/vilanterol (FF/VI) (Relvar Ellipta, ...
PharmaTimes

EU expands scope of GSK/Innoviva’s asthma inhaler

The European Commission has approved a label update to GlaxoSmithKline/Innoviva’s Relvar Ellipta, expanding the asthma therapy’s reach. The European Commission ...
Insider Monkey

Relvar Ellipta: GlaxoSmithKline and Theravance’s Drug for Respiratory Diseases

Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the ...
Business Wire

Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

Trelegy Ellipta is a combination of three molecules in a single inhaler. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, ...
pharmaphorum

GSK’s Relvar Ellipta comes out on top in real world study

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist firm ...
The Financial

Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD

The FINANCIAL — GlaxoSmithKline plc on December 2 announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) ...
Nasdaq

GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma

Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients ...
London South East

RELVAR ELLIPTA Receives Approval in Japan

LONDON, UK, 20 September, 2013 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, announces that the regulatory committee (Bunka-Kai) of the Japanese Ministry of Health ...
London South East

Relvar Ellipta approved in Japan for COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate ...
Medscape

CHMP Backs Revinty Ellipta for Asthma, COPD

The European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the fixed-dose combination of fluticasone furoate and vilanterol (FF/VI) (Revinty ...